Loading market dashboard
IP Group Plc
IPZYFFinancial ServicesOTCGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
IP Group PLC (LSE:IPO), the London-listed science and technology investor, has flagged positive phase II trial results from portfolio company Enterprise Therapeutics for ETD001, its lead candidate for the treatment of cystic fibrosis. The trial evaluated inhaled ETD001 in the 10% of cystic fibrosis patients with the highest unmet medical need, those for whom existing treatments are least effective, and achieved its primary efficacy outcome.
IP Group PLC (LSE:IPO) told investors that its portfolio company Enterprise Therapeutics has reported positive Phase 2 trial results for ETD001, its lead candidate for cystic fibrosis, after the inhaled treatment achieved its primary efficacy outcome. The trial evaluated ETD001's efficacy, safety, tolerability and pharmacokinetics in the 10% of people with cystic fibrosis described as having the highest unmet medical need.
IP Group PLC (LSE:IPO), the LSE-listed science and technology investor, has appointed Michael Queen as non-executive director and chair designate, concluding a succession process announced last year. Queen will take over as chair following the company's annual general meeting on 18 June 2026, when Sir Douglas Flint retires from the board after nearly eight years of service.
First Light Fusion, an IP Group PLC (LSE:IPO) portfolio company developing inertial fusion energy technology, has raised £25 million in the first close of a new funding round led by specialist fusion fund Starmaker One and backed by the UK Atomic Energy Authority (UKAEA). The round was led by East X Ventures, a UK venture firm, through its Starmaker One fusion fund, with a significant strategic investment from the UKAEA, the government body responsible for leading the UK's fusion energy programme.
Frontier IP Group PLC (LSE:FIPP, FRA:8WT) this week highlighted a major funding milestone within its portfolio, as 2D Photonics secured €200 million in Italian state aid to accelerate the scale-up of its graphene-based photonics technology. Chief executive Neil Crabb said the funding, approved under European Union state aid rules, would enable the construction of a pilot manufacturing facility capable of producing 200mm wafers, marking a significant step toward commercial-scale deployment.
IP Group PLC (LSE:IPO), the LSE-listed science and technology investor, has launched a new fund with Australia's Clean Energy Finance Corporation (CEFC) to back cleantech companies targeting hard-to-abate industries. The IP Group Climate Catalyst Fund has a target size of up to A$150 million, with IP Group contributing A$30 million and the CEFC A$20 million as cornerstone investors at first close.
Analysts at three brokerages maintain 'buy' ratings after strong full-year results IP Group PLC (LSE:IPO), the London-listed investor that commercialises intellectual property from leading universities, reported a 13% rise in net asset value (NAV) per share to 110.4p for the year ended December 2025, driven by a licensing deal tied to Pfizer's $10 billion acquisition of obesity drug developer Metsera. The company's shares rose 11% on Tuesday to 54.7p.
Shares in IP Group PLC (LSE:IPO) rose 9% to 53.5p on Monday after the company reported net asset value per share climbing to 110.4p, with total NAV reaching £975.1 million. The recovery was driven largely by Pfizer's acquisition of Metsera, a biotechnology company developing obesity treatments.
The university spinout investor posted a 13% increase in net asset value per share after Pfizer's acquisition of obesity drug developer Metsera IP Group PLC (LSE:IPO), the London-listed investor in university spinout companies, has reported a return to growth in 2025, with net asset value (NAV) per share rising 13% to 110.4 pence and total NAV reaching £975.1 million. The improvement follows a difficult 2024, when NAV per share fell 15% and the group posted a loss of £207 million.
